top of page

Zag Bio launched today with $80M, and aims to tackle autoimmune disease by using antibodies to reprogram how Tregs and Teffs are created in the thymus. The lead indication will be Type 1 diabetes.

  • Oct 28, 2025
  • 1 min read

CEO Jason Cole walks us through this unique science, which is based on work that co-founder Diane Mathis and colleagues published in Cell in 2022. The T1D program is scheduled to be in the clinic by late 2026.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page